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1. Introduction 
Secretion of anterior pituitary luteinizing hormone 
(LH) is controlled by the hypothalamic luteinizing 
hormone-releasing hormone (LH-RH) which has 
recently been isolated [ 1,2] . Crude hypothalamic 
extract containing LH-releasing activity was reported 
to stimulate adenylate cyclase and to increase the 
cyclic AMP level in the pituitary gland [3] . Recently 
it was found that synthetic LH-RH increased adeny- 
late cyclase activity [4] cyclic AMP level and con- 
comitantly stimulated LH release [S-8] . Hence it 
was suggested that cyclic AMP is the mediator of 
LH-RH action on LH release [S-7]. This conclusion 
was further supported by the findings that analogues 
of LH-RH which increased cyclic AMP production 
also caused LH release [9] . The addition of dibutyryl 
cyclic AMP (DBC) to the incubation medium was 
reported to enhance the release of LH [7,10] , while 
other workers found no increase of LH upon the 
addition of this drug [ 11,121 . The present investi- 
gation was intended to clarify whether the increase 
in pituitary cyclic AMP production by LH-RH is 
an obligatory step in LH release. 
2. Materials and methods 
Two-month-old Wistar-derived male rats of the 
departmental colony were housed in air-conditioned 
quarters, illuminated between the hours 05:OO and 
* In partial fulfillment of the requirements for the Ph. D. 
degree of the Graduate School of the Weizmann Institute 
of Science. 
19:O0. Pelleted food (Ralston Purina Co.) and water 
were offered without restriction. 
LH-RH (synthetic decapeptide) was a generous 
gift of Dr N. Yanaihara. Prostaglandin E, (PGE2) 
was generously made available by Dr J. Pike of the 
Upjohn Co., Kalamazoo, Michigan. Flufenamic acid 
(N-(o-a-cw-trifluoro-m-tolyl) anthranilic acid), a gift of 
Rafa Laboratories, Jerusalem, was dissolved in 0.1 N 
NaOH (10 mg/ml). Theophylline (1,3-dimethyl- 
xanthine) was purchased from Sigma Chemical Corp., 
St. Louis, Missouri; IBMX (3-isobutyl-l-methyl- 
xanthine) from Aldrich Chemical Co., Milwaukee, 
Wisconsin and dibutyryl cyclic AMP from Boehringer 
and Siihne, Mannheim. The purified cholera toxin 
(choleragen) used in this study (Lot 1071) was pre- 
pared under contract for the National Institute of 
Allergy and Infectious Diseases (NIAID) by R. A. 
Finkelstein, Ph.D., The University of Texas, South- 
western Medical School, Dallas, Texas [ 131. 
For the in vitro studies, anterior pituitaries were 
cut in half. Two hemipituitaries (derived from differ- 
ent animals), were placed in each flask and initially 
incubated at 37°C for 2 h in 1 ml of Krebs-Ringer 
bicarbonate (KRB) pH 7.4, containing glucose (1 mg/ 
ml). The medium was changed to 1 ml of KRB 
containing various drugs or hormones as indicated 
in the text, and the incubation was continued for 
another 4 h. At the end of the incubation period, 
ahquots of the medium were analyzed for LH 
content by radioimmunoassay [ 141 and the slices 
were placed immediately in tubes containing hot 
Na-acetate buffer pH 4.0. The content of cyclic 
AMP was determined by a competitive protein 
binding assay [ 151. 
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3. Results 
Incubation of hemipituitaries for 4 h with LH-RH, 
PGEz , choleragen, theophylline or IBMX, raised 
pituitary cyclic AMP accumulation by a factor of 4, 
13, 27, 5, and 5, respectively (fig.1). However, only 
LH-RH stimulated LH release into the medium (3- 
fold increase; fig.1). Dibutyryl cyclic AMP (1 mM; 
fig.l) and 1 mM 8-bromo-cyclic AMP (data no shown) 
were without effect on LH release. 
Flufenamic acid (3-100 pg/ml) did not influence 
pituitary cyclic AMP accumulation; however at 10 pg/ 
ml or higher concentration the drug abolished LH- 
RH stimulation of cyclic AMP production. Never- 
theless, flufenamic acid (10 ,ug/ml) did not inhibit 
LH-RH stimulation of LH release into the medium 
(ftg.2). At high concentration (100 fig/ml), the drug 
on its own caused LH release (70%). 
4. Discussion 
Cyclic AMP is implicated in the mechanism of 
action of many protein and peptide hormones. Since 
the pituitary adenylate cyclase-cyclic AMP system 
was recently shown to be stimulated by LH--RH in 
vitro [.5-8f, it was suggested that cyclic AMP is an 
essential mediator in the mechanism of LH--RH 
action on LH release 15-71. However, under various 
experimental conditions we were able to dissociate 
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Fig.1. In vitro effects of LH-RH, PGE,, &kzagen (cholera), theophy~ine (theop), IBMX and dibutyryl cyclic AMP-(DBC~ on 
LH release (A) and cyclic AMPlevel in the pituitary (B). Bisected anterior pituitaries were incubated for 2 h in KRB. The medium 
was then changed to KRB containing the drugs indicated, and the incubation was continued for another 4 h. At the end of the 
incubation period, aliquots of the medium were analyzed for LH content by radioimmunoassay and pituitaries were taken to 
cyclic AMP determination as described in Materials and methods. Basal LH release to the medium was 18.5 c 2.0 pg/ml, and basal 
cyclic AMP level was 0.44 +_ 0.04 pmol/mg tissue wet weight. Vertical brackets indicate S. E. M. for 10 determinations. 
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F lufenomlc acid concentratlcn (Kg/ml) 
E‘ig.2. Effect of flufcnamic acid on the stimulatory action of 
LH1RI1 on LH release (A) and cyclic AMP accumulation (B) 
by the pituitary in vitro. Anterior pituitaries were incubated 
for 2 h in KRB. The medium was then changed and various 
doses of flufenamic acid (O-100 &ml) alone (A--A), or 
together with 25 ng/ml of LH-RH (o-o), were added. 
The incubation was continued for another 4 h. At the end of 
the incubation period aliquots of the medium were analyzed 
for LH content and the pituitaries for cyclic AMP content 
as described above. BasaI LH released to the medium was 
28.5 f 4 &ml. Vertical brackets indicate S. E. M. for 10 
determinations. 
between the action of LH-RH on cyclic AMP 
production and on LH release. 
While there is a general agreement hat PGE 
increases pituitary cyclic AMP production [3,4,7,16] 
reports differ as to the effect of PGE on LH release. 
Makino [7] and Ratner et al. [16] found increased 
LH release when PGE was added to incubated pitu- 
itaries, but other workers failed to find any increase 
in LH release after short [ 171 or long incubation 
periods with PGE ([ 181 and present results fig.1). 
The disagreement concerning the PGE effect on LH 
release might be explained by strain differences 
between the animals used, or by the use of different 
types of prostaglandins (PGE2 versus PGE, ). A simi- 
lar dissociation between cyclic AhIP increase and LH 
release was observed when another stimulator of 
adenylate cyclase, namely choleragen, was incubated 
with pituitaries (fig. 1). Since the gonadotrophs 
constitute only 5-10% of the pituitary cell popu- 
lation, it could be argued that PGE, and choleragen 
affect pituitary cell types other than the gonado- 
trophs and hence had no effect on LH release. How- 
ever, it seems unlikely that these non-specific drugs 
differentiate between the gonadotrophs and other 
pituitary cell types. Furthermore, incubation of 
pituitaries with theophylline (1 mM) or relatively 
small amounts of IBMX (0.06 mM) increase pituitary 
cyclic AMP accumulation without affecting LH 
release (fig.1). These drugs probably inhibit phos- 
phodiesterase activity in all the different cell types. 
Thus it seems to us that the effect is exerted on all 
the different cell types, and that the increase in 
cyclic AMP is not relevant to stimulation of LH 
release. Addition of cyclic AMP derivatives like 
dibutyryl cyclic AMP (DBC) and %bromo-cyclic 
AMP to the incubation medium did not stimulate LH 
release ([ 11 .12] and present results, f&.1), which 
strengthens this conclusion. It might be argued that 
these cyclic AMP derivatives do not penetrate the 
gonadotrophs. However, Makino [7] found stimu- 
lation of LH release upon the addition of DBC to 
incubated pituitaries. Isolated gonadotrophs might 
serve as a suitable tool for further investigation 
concerning this problem. 
In recent studies (data not shown) we observed a 
difference in responsiveness to LH-RH between male 
and female rats. While in the male we could always 
observe an increase in cyclic AMP and LH release, 
in response to LH%RH in vitro, in female rats no 
increase in cyclic AMP was observed in some experi- 
ments, although LH release was stimulated. 
In a different set of conditions it was possible to 
demonstrate a stimulatory action of LH-RH on 
pituitary LH release without an effect on cyclic AMP 
production: flufenamic acid (10 pg/ml) abolished 
LH-RH stimulation of cyclic AMP production but 
did not affect its action on LH release (fig.2). 
The possibility that elevation of cyclic AMP by 
LH-RH or its analogues [6,9] may mediate the 
effect of LH-RH on LH biosynthesis is not excluded 
by the present experiments. However, the present 
results and recent studies [17,19,20] suggest hat the 
stimulation of pituitary cyclic AMP formation by 
LI-I-RH is not an obligatory step in the mechanism 
of LH release. 
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